- Home
- ARHS vs MGTX Comparison
ARHS vs MGTX Comparison
Compare ARHS & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARHS | MGTX |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.8M | 1.0B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ARHS | MGTX |
|---|---|---|
| Price | $11.11 | $10.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 8 |
| Target Price | $10.85 | ★ $27.75 |
| AVG Volume (30 Days) | ★ 1.5M | 983.5K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | 0.30 | ★ 1.30 |
| Revenue | ★ $1,379,222,000.00 | $81,391,000.00 |
| Revenue This Year | $5.94 | $314.19 |
| Revenue Next Year | $6.53 | N/A |
| P/E Ratio | $35.67 | ★ $7.67 |
| Revenue Growth | 8.51 | ★ 144.57 |
| 52 Week Low | $5.57 | $6.62 |
| 52 Week High | $12.08 | $15.35 |
Technical Indicators
Market Signals| Indicator | ARHS | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 69.51 | 39.63 |
| Support Level | $9.42 | $8.84 |
| Resistance Level | $11.23 | $10.06 |
| Average True Range (ATR) | 0.42 | 0.50 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 97.66 | 44.54 |
Price Performance
Historical ComparisonAbout ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.